Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Total Liabilities (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed Total Liabilities for 15 consecutive years, with $16.5 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 15.83% to $16.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.5 million through Dec 2025, up 15.83% year-over-year, with the annual reading at $16.5 million for FY2025, 15.83% up from the prior year.
  • Total Liabilities hit $16.5 million in Q4 2025 for Cardiff Oncology, up from $15.0 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $17.1 million in Q2 2025 to a low of $4.8 million in Q1 2021.
  • Historically, Total Liabilities has averaged $11.4 million across 5 years, with a median of $10.8 million in 2022.
  • Biggest five-year swings in Total Liabilities: fell 16.17% in 2021 and later skyrocketed 123.98% in 2022.
  • Year by year, Total Liabilities stood at $9.1 million in 2021, then grew by 7.9% to $9.8 million in 2022, then grew by 20.82% to $11.9 million in 2023, then increased by 19.69% to $14.2 million in 2024, then rose by 15.83% to $16.5 million in 2025.
  • Business Quant data shows Total Liabilities for CRDF at $16.5 million in Q4 2025, $15.0 million in Q3 2025, and $17.1 million in Q2 2025.